Lumenis Announces Sale of 1000th Selecta^® SLT Laser Worldwide

Yokneam, Israel, October 4, 2005 – Lumenis^® Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced the sale of the one-thousandth Selecta SLT Laser for selective photo therapy of glaucoma.

Glaucoma is the second leading cause of preventable blindness worldwide and a silent disease that often goes untreated before significant damage is done. “We’re pleased with the growing interest in SLT for its potential to prevent blindness. Achieving this important milestone in terms of sales of our systems is a solid indication of the expanding acceptance of SLT as a preferred treatment for glaucoma,” commented Lumenis President and Chief Executive Officer, Avner Raz. “Clinical data and patient satisfaction continue to convince doctors that SLT is an effective treatment for their glaucoma patients, both in terms of optimal patient compliance and overall therapy cost. While we have made significant progress in the United States, we strive to increase the use of this important sight-preserving alternative in our other global regions, since they represent the vast majority of glaucoma prevalence worldwide.”

Dr. Mark Latina, the inventor of SLT, stated, “I knew this would be a breakthrough technology and embraced by the ophthalmic community. SLT has become a widely accepted glaucoma treatment and popular enough that patients ask me about it by name. Patients are now using less medication or no medications, and proactively asking for the SLT treatment. To me, that is the ultimate goal – patient satisfaction.”

The use of SLT has increased rapidly, since Lumens’ family of Selecta^® laser systems gained FDA clearance in 2001. This new therapy has demonstrated to clinicians the ability to reduce the need for on-going and repeated medication or therapy, which directly addresses patient compliance concerns. After an SLT treatment, the body’s own mechanism is activated, which lowers eye pressure and effectively treats the glaucoma patient.

While adoption of SLT in the US has been remarkably high, Lumenis has identified and will pursue the untapped markets in Asia Pacific and Europe. Avner Raz further noted, “Available estimates suggest there are 70 million glaucoma patients worldwide and open-angle glaucoma is the most common form of this condition. Only 3 million of these glaucoma patients are in the United States. Furthermore, the incidence of glaucoma is expected to increase as the global population ages. We are uniquely positioned to address this growing global need.”

Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com.


Contact:

Lauri Hanover, CFO
1-866-232-6803
+972-4-959-9122

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of its Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.